Ironwood Pharmaceuticals (IRWD)
(Delayed Data from NSDQ)
$4.98 USD
+0.29 (6.18%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.98 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
C Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.98 USD
+0.29 (6.18%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.98 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
C Value C Growth D Momentum D VGM
Zacks News
Ironwood Pharmaceuticals (IRWD) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of 4.17% and 4.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.60% and 35.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Xencor (XNCR): Can Its 5.3% Jump Turn into More Strength?
by Zacks Equity Research
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Increases
by Zacks Equity Research
Though Ironwood (IRWD) missed both Q4 earnings and sales estimates, the total prescription demand for the sole-marketed drug Linzess rose 9% year over year.
Ironwood Pharmaceuticals (IRWD) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of -3.57% and 3.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Q4 Earnings Due on Feb 16: ALKS, RARE & Others
by Zacks Equity Research
Let's look at the four biotech/drug companies slated to release quarterly results on Feb 16.
BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ironwood (IRWD) Gets FDA Priority Tag for Linzess sNDA
by Zacks Equity Research
With the FDA granting priority review to Ironwood Pharmaceuticals' (IRWD) sNDA seeking label expansion of Linzess for functional constipation in kids, a decision is expected in the second quarter of 2023.
Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie (ABBV) Vraylar Gets FDA Nod for Major Depressive Disorder
by Zacks Equity Research
FDA approves AbbVie's (ABBV) Vraylar (cariprazine) for its fourth indication - the adjunctive treatment of patients with MDD.
Catalyst (CPRX) Up 8.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ironwood's (IRWD) Q3 Earnings Beat, Linzess Volume Grows
by Zacks Equity Research
Ironwood (IRWD) beat earnings estimates in the third quarter. Sales, though missing estimates, rose year over year. Stock up.
Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of 3.70% and 2.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Ironwood's (IRWD) Functional Constipation Study in Kids Succeeds
by Zacks Equity Research
Ironwood (IRWD) reports positive top-line data from a late-stage study evaluating Linzess (linaclotide) for functional constipation in pediatric patients aged six to 17 years.
Ironwood (IRWD) Q2 Earnings Miss, Keeps 2022 Sales Guidance
by Zacks Equity Research
Ironwood (IRWD) miss earnings and revenue estimates in the second quarter. Stock declines.
Ironwood Pharmaceuticals (IRWD) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of -32.26% and 2.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Ironwood (IRWD) Q1 Earnings Miss, Linzess Growth Continues
by Zacks Equity Research
Ironwood (IRWD) witnesses strong year-over-year sales growth on continued demand for Linzess. Its first-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines.
Ironwood Pharmaceuticals (IRWD) Q1 Earnings Miss Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of -22.22% and 2.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in BioCryst (BCRX): Can Its 15.2% Jump Turn into More Strength?
by Zacks Equity Research
BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Ironwood Pharmaceuticals (IRWD) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Grows
by Zacks Equity Research
Ironwood (IRWD) witnesses flat year-over-year sales growth. Its fourth-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines.
Medical Stocks' Q4 Earnings on Feb 17: RGEN, IRWD & More
by Indrajit Bandyopadhyay
Let us take a look at four biotech or drug companies - RGEN, IRWD, EXEL and LGND - due to release their quarterly results on Feb 16.
Is Ironwood Pharmaceuticals (IRWD) a Suitable Stock for Value Investors?
by Zacks Equity Research
Is Ironwood Pharmaceuticals (IRWD) a great pick from the value investor's perspective right now? Read on to know more.
Ironwood (IRWD) Q3 Earnings Top, Sales Hurt by Lower Price
by Zacks Equity Research
Ironwood (IRWD) witnesses flat year-over-year sales as growth in demand for Linzess gets partially offset by lower net price of the drug. The company maintains revenue guidance. Stock down.